Biotech RadarJobs updated

COMPANY

Insmed

HQ: Utrecht, Netherlands source · insmed.com ↗ · Mid-Atlantic

FDA-approved therapeutic company Clinical Phase 3

116 open jobs · last seen Oct 23, 2026 · 54 sources

Insmed is founded as a private company by Dr. Joseph Larner in Charlottesville, VA, to develop medicines to treat diabetes. We are advancing a diverse portfolio of investigational medicines aimed at addressing a range of serious diseases. From company website Source · Oct 13, 2026

Keywords: investigational medicines Pulmonary Hypertension Interstitial Lung Disease Pulmonary Arterial Hypertension Cystic Fibrosis Nontuberculous Mycobacterium Infections Non-Cystic Fibrosis Bronchiectasis Hepatic Impairment Bronchiectasis Chronic Rhinosinusitis Without Nasal Polyps Atopic Dermatitis Progressive Pulmonary Fibrosis Hidradenitis Suppurativa Renal Impairment Myotonic Dystrophy Type 1 Pseudomonas Aeruginosa Infection NTM Lung Infection Due to MAC Osteosarcoma Metastatic Growth Hormone Insensitivity Syndrome Laron Syndrome Noonan Syndrome lung infection polycystic ovary syndrome polycystic ovary Treprostinil Palmitil Brensocatib rhIGF-I/rhIGFBP-3 INS1033 OpSCF SLIT™ Amikacin INS1007 Arikayce™ ARIKACE™ Cisplatin liposomal

Since the raise (Jun 11, 2025): 116 of 116 open jobs were first seen after it.

116Open jobs$750.0MRaised (2 yrs)50Trials (company is sponsor)1FDA records (2 yrs)5NIH grants

Hiring

TitleLocation (from posting)Employer postedFirst seen
QMS Specialist, Quality AssuranceResearch Development Lab - San DiegoOct 22, 2026Oct 18, 2026
Senior Director, Regulatory AffairsNJ Corporate HeadquartersOct 22, 2026Oct 23, 2026
Manager, MarketingJapanOct 21, 2026Oct 20, 2026
Senior Manager, Facilities MaintenanceNJ Corporate HeadquartersOct 21, 2026Oct 22, 2026
Summer Intern – Bioanalysis ResearchResearch Development Lab - New JerseyOct 21, 2026Oct 22, 2026

See all 116 jobs

Timeline

  1. Trial start Phase 3: A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF) source ↗
  2. Trial start Phase 1: A Study to Assess the Potential CYP3A Induction Effect of Brensocatib on the Pharmacokinetics (PK) of Midazolam in Healthy Participants source ↗
  3. Board tracked Radar started tracking this company’s job board (116 open jobs at last check). source ↗
  4. Trial start Phase 1: A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of INS1033 in Healthy Participants source ↗
  5. Trial start Phase 3: A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH) source ↗
  6. Trial start Phase 3: An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) source ↗
  7. Trial start Phase 1: A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With source ↗
  8. Trial start Phase 3: Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) source ↗
  9. Trial start Phase 1: A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Heal source ↗
  10. FDA FDA New drug/biologic (novel): BRINSUPRI (brensocatib) — NDA217673, Aug 12, 2025. Applicant at approval: Insmed Incorporated. source ↗
  11. Raise Follow-on offering: $750M (total, as published), announced Jun 11, 2025. Source: SEC filing. source ↗
  12. Debt Debt: $569.5M (not counted as a raise), announced Apr 24, 2025. Source: SEC filing. source ↗
  13. Trial start Phase 2: A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS) source ↗
  14. Trial start Phase 1: A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants source ↗
  15. Trial start Phase 1: A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants source ↗
  16. Trial start 2: Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis) source ↗
  17. Trial start Phase 2: A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) source ↗
  18. Trial start Phase 1: A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants source ↗
  19. Trial start Phase 2/Phase 3: An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) source ↗
  20. Trial start Phase 1: A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants source ↗
  21. Trial start Phase 2/Phase 3: An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) source ↗
  22. Trial start Phase 2: A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease source ↗
  23. Trial start Phase 1: A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment source ↗
  24. Trial start Phase 2: A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension source ↗
  25. Trial start Phase 1: A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants source ↗

Showing 25 of 49 dated events.

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 116

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
QMS Specialist, Quality AssuranceResearch Development Lab - San DiegoOct 22, 2026Oct 18, 2026Not stated
Senior Director, Regulatory AffairsNJ Corporate HeadquartersOct 22, 2026Oct 23, 2026Not stated
Manager, MarketingJapanOct 21, 2026Oct 20, 2026Not stated
Senior Manager, Facilities MaintenanceNJ Corporate HeadquartersOct 21, 2026Oct 22, 2026Not stated
Summer Intern – Bioanalysis ResearchResearch Development Lab - New JerseyOct 21, 2026Oct 22, 2026Not stated
Director, DSPV Data, Technology and InnovationNJ Corporate HeadquartersOct 20, 2026Oct 9, 2026Senior
Early Development Program Lead – Cambridge2 locations (listed on the posting)Oct 20, 2026Oct 9, 2026Senior
Early Development Program Lead – NH/NJ2 locations (listed on the posting)Oct 20, 2026Oct 9, 2026Senior
Scientist, Biologics ResearchResearch Development Lab - New JerseyOct 20, 2026Oct 21, 2026Not stated
Vice President and Global Head of Drug Safety and PharmacovigilanceNJ Corporate HeadquartersOct 19, 2026Oct 9, 2026Executive
Senior Director, Regulatory Affairs CMCNJ Corporate HeadquartersOct 19, 2026Oct 9, 2026Senior
Associate Director, ProgrammingNJ Corporate HeadquartersOct 19, 2026Oct 20, 2026Not stated
Director, BiostatisticsNJ Corporate HeadquartersOct 18, 2026Oct 19, 2026Not stated
Senior Director, Program ManagementResearch Development Lab - San DiegoOct 16, 2026Oct 9, 2026Senior
Senior Director, PMO Strategic Portfolio Management & AI InnovationNJ Corporate HeadquartersOct 16, 2026Oct 9, 2026Senior
Medical Science Liaison - Los Angeles/Southern California6 locations (listed on the posting)Oct 16, 2026Oct 18, 2026Not stated
Sr. Director, Regulatory Affairs, Global Regulatory Lead - Development StrategyNJ Corporate HeadquartersOct 15, 2026Oct 15, 2026Senior
Summer Intern - Clinical DevelopmentNJ Corporate HeadquartersOct 15, 2026Oct 16, 2026Not stated
Director, Medical SafetyNJ Corporate HeadquartersOct 15, 2026Oct 16, 2026Not stated
Senior Director, Regulatory Affairs CMC - Gene Therapy2 locations, including San Diego, Research Development LabOct 14, 2026Oct 15, 2026Senior
Associate Director, Disease Diagnosis AccelerationNJ Corporate HeadquartersOct 14, 2026Oct 15, 2026Senior
Senior Analyst, Quality AssuranceResearch Development Lab - San DiegoOct 13, 2026Oct 9, 2026Senior
Director Medical Insights & AnalyticsNJ Corporate HeadquartersOct 13, 2026Oct 9, 2026Senior
Legal Applications Senior Lead – CLM & Legal TechnologyNJ Corporate HeadquartersOct 13, 2026Oct 9, 2026Senior
Summer Intern - Development OperationsNJ Corporate HeadquartersOct 13, 2026Oct 14, 2026Entry
Director, Quality Assurance AI/ML SystemsNJ Corporate HeadquartersOct 12, 2026Oct 13, 2026Senior
Director, Gene Therapy CMC LeadNJ Corporate HeadquartersOct 12, 2026Oct 13, 2026Senior
Therapeutic Specialist, Sacramento WestSacramento, CAOct 12, 2026Oct 13, 2026Mid
Global Medical Affairs Head, Neuro/Other RareNJ Corporate HeadquartersOct 12, 2026Oct 13, 2026Executive
Vice President, Program Management & PMONJ Corporate HeadquartersOct 11, 2026Oct 11, 2026Executive
Research Associate, Gene TherapyResearch Development Lab - San DiegoOct 9, 2026Oct 9, 2026Entry
Therapeutic Specialist - Kansas City EastKansas City E, MOOct 9, 2026Oct 9, 2026Mid
Senior Director, DSPV Quality, Training & ComplianceNJ Corporate HeadquartersOct 9, 2026Oct 9, 2026Senior
Senior Manager, Clinical Supplier QualityNJ Corporate HeadquartersOct 8, 2026Oct 9, 2026Senior
Associate Director, Medical Science Liaison - Michigan, Indiana10 locations (listed on the posting)Oct 8, 2026Oct 9, 2026Senior
Associate Director, Medical Science Liaison (Los Angeles, NV)4 locations (listed on the posting)Oct 8, 2026Oct 9, 2026Senior
Associate Director, Medical Science Liaison - Minnesota, Iowa, Missouri8 locations (listed on the posting)Oct 8, 2026Oct 9, 2026Senior
Associate Director, Medical Science Liaison - Wisconsin, Illinois5 locations (listed on the posting)Oct 8, 2026Oct 9, 2026Senior
Associate Director, Medical Science Liaison - Ohio, Kentucky, TennesseeNJ Corporate HeadquartersOct 8, 2026Oct 9, 2026Senior
Associate Director, Medical Science Liaison - Pennsylvania6 locations (listed on the posting)Oct 8, 2026Oct 9, 2026Senior
Associate Director, Medical Science Liaison - Gulf Coast6 locations (listed on the posting)Oct 8, 2026Oct 9, 2026Senior
Director, Talent & Workforce StrategyNJ Corporate HeadquartersOct 8, 2026Oct 9, 2026Senior
Summer Intern – Protein EngineeringResearch Development Lab - New HampshireOct 8, 2026Oct 9, 2026Entry
Summer Intern – CMC Quality Assurance, Clinical ProgramsNJ Corporate HeadquartersOct 8, 2026Oct 9, 2026Entry
Summer Intern – Quality Systems & Business ProcessesNJ Corporate HeadquartersOct 8, 2026Oct 9, 2026Entry
Summer Intern - Biologics ResearchResearch Development Lab - New HampshireOct 8, 2026Oct 9, 2026Entry
Senior Associate, Early Career ProgramsNJ Corporate HeadquartersOct 7, 2026Oct 9, 2026Mid
Compliance Manager, Clinical Supply ChainNJ Corporate HeadquartersOct 7, 2026Oct 9, 2026Mid
Senior Director, Therapeutic Area Insights – Neuro & Other RareNJ Corporate HeadquartersOct 7, 2026Oct 9, 2026Senior
Field Access Manager, Miami-Puerto Rico2 locations (listed on the posting)Oct 6, 2026Oct 9, 2026Mid

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

All 116 jobs →

Funding

Raised: $750.0M · Debt: $569.5M. Last 2 years.

Clinical trials (lead sponsor) 50

RecordTitlePhaseStatusStartPrimary completion
NCT07859007A Study to Assess the Potential CYP3A Induction Effect of Brensocatib on the Pharmacokinetics (PK) of Midazolam in Healthy ParticipantsPhase 1Not yet recruitingOct 29, 2026Nov 25, 2026 (estimated)
NCT06013241A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)Phase 2CompletedOct 30, 2023Sep 30, 2025 (actual)
NCT07179380Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Phase 3RecruitingJan 7, 2026Dec 30, 2028 (estimated)
NCT07765706A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of INS1033 in Healthy ParticipantsPhase 1RecruitingAug 25, 2026Mar 22, 2027 (estimated)
NCT07481981A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)Phase 3RecruitingJul 21, 2026Dec 28, 2028 (estimated)
NCT07643155A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic ImpairmentPhase 1RecruitingJul 14, 2026Feb 7, 2027 (estimated)
NCT06101823Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis)2CompletedNov 21, 2023Sep 3, 2024 (actual)
NCT07805785A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)Phase 3Not yet recruitingDec 1, 2026Aug 31, 2030 (estimated)
NCT05649748An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)Phase 2/Phase 3Active, not recruitingMar 7, 2023Dec 31, 2026 (estimated)
NCT07234032An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Phase 3RecruitingJul 20, 2026Jan 22, 2031 (estimated)
NCT06685835A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)Phase 2TerminatedDec 16, 2024Feb 12, 2026 (actual)
NCT06939647An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Not listedAvailableNot listedNot listed
NCT05649722An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Phase 2/Phase 3CompletedMay 11, 2023Apr 1, 2026 (actual)
NCT05147805A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial HypertensionPhase 2CompletedAug 24, 2022Mar 27, 2025 (actual)
NCT05090904A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic FibrosisPhase 2CompletedNov 30, 2021Nov 1, 2022 (actual)
NCT04677569Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium ComplexPhase 3CompletedApr 1, 2021Nov 21, 2025 (actual)
NCT04594369A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis BronchiectasisPhase 3CompletedDec 1, 2020Oct 28, 2024 (actual)
NCT07102316A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy ParticipantsPhase 1CompletedAug 19, 2025Oct 25, 2025 (actual)
NCT05344508An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis BronchiectasisNot listedApproved for marketingNot listedNot listed
NCT05176951A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung DiseasePhase 2CompletedDec 22, 2022Mar 14, 2024 (actual)
NCT04677543Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium ComplexPhase 3CompletedDec 22, 2020May 9, 2023 (actual)
NCT06344728A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy ParticipantsPhase 1CompletedApr 30, 2024May 24, 2024 (actual)
NCT06238856Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLIT™] Amikacin) in Participants With Cystic Fibrosis (CF) Having Chronic Infections of Pseudomonas AeruginosaPhase 1CompletedMay 12, 2004Feb 8, 2005 (actual)
NCT06178783A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy ParticipantsPhase 1CompletedDec 27, 2023Jan 4, 2024 (actual)
NCT06193031A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy ParticipantsPhase 1CompletedNov 17, 2015Dec 18, 2015 (actual)
NCT05965570A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy ParticipantsPhase 1CompletedJul 28, 2023Sep 22, 2023 (actual)
NCT06091579A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy ParticipantsPhase 1CompletedSep 17, 2020Jan 12, 2021 (actual)
NCT04791514A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)Phase 2TerminatedMar 29, 2022Aug 26, 2022 (actual)
NCT05999942A Study to Investigate Lung Deposition of Inhaled Amikacin-loaded Liposomes in Healthy Male ParticipantsPhase 1CompletedJun 2, 2004Jun 29, 2004 (actual)
NCT05826574A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy ParticipantsPhase 1CompletedMay 10, 2023Jul 16, 2023 (actual)
NCT05517525A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic ImpairmentPhase 1CompletedOct 4, 2022Jun 1, 2023 (actual)
NCT05927597A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Caucasian ParticipantsPhase 1CompletedJan 9, 2019Aug 1, 2019 (actual)
NCT05673603A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal ImpairmentPhase 1CompletedJul 20, 2021Feb 14, 2023 (actual)
NCT03218917Assessment of INS1007 in Participants With Non-Cystic Fibrosis BronchiectasisPhase 2CompletedOct 31, 2017Dec 12, 2019 (actual)
NCT05355935A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy ParticipantsPhase 1CompletedApr 27, 2022Oct 7, 2022 (actual)
NCT05652257A Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral Administration in Healthy Male ParticipantsPhase 1CompletedAug 13, 2021Sep 14, 2021 (actual)
NCT00577577Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1Phase 2Completed2007-12Dec 29, 2008 (actual)
NCT03905642Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension PhasePhase 2CompletedJan 8, 2009Nov 2, 2010 (actual)
NCT00777296Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)Phase 1/Phase 2CompletedFeb 22, 2007Feb 27, 2008 (actual)
NCT01316276Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) InfectionPhase 3CompletedOct 5, 2012Jul 16, 2015 (actual)
NCT01315678Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa InfectionsPhase 3CompletedFeb 29, 20122013-06 (actual)
NCT02344004Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen AlonePhase 3CompletedMay 27, 2015Jul 3, 2018 (actual)
NCT02628600Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212Phase 3CompletedFeb 5, 2016Oct 17, 2018 (actual)
NCT01315236Liposomal Amikacin for Inhalation (LAI) for Nontuberculous MycobacteriaPhase 2CompletedApr 19, 2012Aug 18, 2014 (actual)
NCT00775138Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.Phase 2CompletedJun 24, 2008May 11, 2009 (actual)
NCT00558844Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas AeruginosaPhase 1/Phase 2Completed2008-012009-06 (actual)
NCT01315691Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas AeruginosaPhase 3WithdrawnNot listedNot listed
NCT00102531Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the LungPhase 1/Phase 2CompletedJan 12, 20052008-03 (actual)
NCT00368173IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron SyndromePhase 2/Phase 3CompletedNot listedNot listed
NCT00351221Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan SyndromePhase 2TerminatedNot listedNot listed

FDA records (last 2 years)

NIH awards 5

Annual award amounts. Total $2.9M.

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Connect

See your connections at Insmed on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12

Feedback